ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000A51

Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss

Identifieur interne : 000A51 ( PascalFrancis/Corpus ); précédent : 000A50; suivant : 000A52

Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss

Auteurs : Yoshiaki Furukawa

Source :

Advances in neurology [ 0091-3952 ] ; 2003.

RBID : Pascal:03-0414553

Descripteurs français

Pascal (Inist)
- Dopa, Tyrosine, Dystonie, Traitement, Hydroxylase, Chimiothérapie, Homme, Aminoacide.

English descriptors

KwdEn :
- Aminoacid, Chemotherapy, Dopa, Dystonia, Human, Hydroxylase, Treatment, Tyrosine.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0091-3952`
A02	`01`			`@0 ADNRA3`
A03		`1`		`@0 Adv. neurol.`
A05				`@2 91`
A08	`01`	`1`	`ENG`	`@1 Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss`
A09	`01`	`1`	`ENG`	`@1 Parkinson's Disease`
A11	`01`	`1`		`@1 FURUKAWA (Yoshiaki)`
A12	`01`	`1`		`@1 GORDIN (Ariel) @9 ed.`
A12	`02`	`1`		`@1 KAAKKOLA (Seppo) @9 ed.`
A12	`03`	`1`		`@1 TERÄVÄINEN (Heikki) @9 ed.`
A14	`01`			`@1 Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division @2 Toronto, Ontario @3 CAN @Z 1 aut.`
A15	`01`			`@1 Research Centre, Orion Pharma, Orionintie 1 @2 02100 Espoo @3 FIN @Z 1 aut.`
A15	`02`			`@1 Department of Neurology, University of Helsinki @2 Helsinki @3 FIN @Z 2 aut. @Z 3 aut.`
A20				`@1 401-410`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15741 @5 354000118596840410`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 68 ref.`
A47	`01`	`1`		`@0 03-0414553`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Advances in neurology`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Dopa @2 NK @2 FR @5 02`
C03	`01`	`X`	`ENG`	`@0 Dopa @2 NK @2 FR @5 02`
C03	`01`	`X`	`SPA`	`@0 Dopa @2 NK @2 FR @5 02`
C03	`02`	`X`	`FRE`	`@0 Tyrosine @2 NK @2 FR @5 03`
C03	`02`	`X`	`ENG`	`@0 Tyrosine @2 NK @2 FR @5 03`
C03	`02`	`X`	`SPA`	`@0 Tirosina @2 NK @2 FR @5 03`
C03	`03`	`X`	`FRE`	`@0 Dystonie @5 04`
C03	`03`	`X`	`ENG`	`@0 Dystonia @5 04`
C03	`03`	`X`	`SPA`	`@0 Distonía @5 04`
C03	`04`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`04`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`04`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`05`	`X`	`FRE`	`@0 Hydroxylase @2 FE @5 18`
C03	`05`	`X`	`ENG`	`@0 Hydroxylase @2 FE @5 18`
C03	`05`	`X`	`SPA`	`@0 Hydroxylase @2 FE @5 18`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 19`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 19`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 19`
C03	`07`	`X`	`FRE`	`@0 Homme @5 21`
C03	`07`	`X`	`ENG`	`@0 Human @5 21`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 21`
C03	`08`	`X`	`FRE`	`@0 Aminoacide @5 25`
C03	`08`	`X`	`ENG`	`@0 Aminoacid @5 25`
C03	`08`	`X`	`SPA`	`@0 Aminoácido @5 25`
C07	`01`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme`
C07	`02`	`X`	`ENG`	`@0 Enzyme`
C07	`02`	`X`	`SPA`	`@0 Enzima`
C07	`03`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 37`
C07	`03`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`03`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`04`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`04`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`04`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`05`	`X`	`FRE`	`@0 Muscle strié pathologie @5 39`
C07	`05`	`X`	`ENG`	`@0 Striated muscle disease @5 39`
C07	`05`	`X`	`SPA`	`@0 Músculo estriado patología @5 39`
C07	`06`	`X`	`FRE`	`@0 Système nerveux pathologie @5 40`
C07	`06`	`X`	`ENG`	`@0 Nervous system diseases @5 40`
C07	`06`	`X`	`SPA`	`@0 Sistema nervioso patología @5 40`
C07	`07`	`X`	`FRE`	`@0 Trouble neurologique @5 41`
C07	`07`	`X`	`ENG`	`@0 Neurological disorder @5 41`
C07	`07`	`X`	`SPA`	`@0 Trastorno neurológico @5 41`
C07	`08`	`X`	`FRE`	`@0 Encéphale pathologie @5 42`
C07	`08`	`X`	`ENG`	`@0 Cerebral disorder @5 42`
C07	`08`	`X`	`SPA`	`@0 Encéfalo patología @5 42`
C07	`09`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 43`
C07	`09`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`09`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 286`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0414553 INIST
ET :	Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss
AU :	FURUKAWA (Yoshiaki); GORDIN (Ariel); KAAKKOLA (Seppo); TERÄVÄINEN (Heikki)
AF :	Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division/Toronto, Ontario/Canada (1 aut.); Research Centre, Orion Pharma, Orionintie 1/02100 Espoo/Finlande (1 aut.); Department of Neurology, University of Helsinki/Helsinki/Finlande (2 aut., 3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Advances in neurology; ISSN 0091-3952; Coden ADNRA3; Etats-Unis; Da. 2003; Vol. 91; Pp. 401-410; Bibl. 68 ref.
LA :	Anglais
CC :	002B17G
FD :	Dopa; Tyrosine; Dystonie; Traitement; Hydroxylase; Chimiothérapie; Homme; Aminoacide
FG :	Oxidoreductases; Enzyme; Extrapyramidal syndrome; Mouvement involontaire; Muscle strié pathologie; Système nerveux pathologie; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie
ED :	Dopa; Tyrosine; Dystonia; Treatment; Hydroxylase; Chemotherapy; Human; Aminoacid
EG :	Oxidoreductases; Enzyme; Extrapyramidal syndrome; Involuntary movement; Striated muscle disease; Nervous system diseases; Neurological disorder; Cerebral disorder; Central nervous system disease
SD :	Dopa; Tirosina; Distonía; Tratamiento; Hydroxylase; Quimioterapia; Hombre; Aminoácido
LO :	INIST-15741.354000118596840410
ID :	03-0414553

Links to Exploration step

Pascal:03-0414553

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss</title>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0414553</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0414553 INIST</idno>
<idno type="RBID">Pascal:03-0414553</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A51</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss</title>
<author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name>
<affiliation><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Advances in neurology</title>
<title level="j" type="abbreviated">Adv. neurol.</title>
<idno type="ISSN">0091-3952</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aminoacid</term>
<term>Chemotherapy</term>
<term>Dopa</term>
<term>Dystonia</term>
<term>Human</term>
<term>Hydroxylase</term>
<term>Treatment</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopa</term>
<term>Tyrosine</term>
<term>Dystonie</term>
<term>Traitement</term>
<term>Hydroxylase</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Aminoacide</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0091-3952</s0>
</fA01>
<fA02 i1="01"><s0>ADNRA3</s0>
</fA02>
<fA03 i2="1"><s0>Adv. neurol.</s0>
</fA03>
<fA05><s2>91</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Parkinson's Disease</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>FURUKAWA (Yoshiaki)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>GORDIN (Ariel)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>KAAKKOLA (Seppo)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>TERÄVÄINEN (Heikki)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Research Centre, Orion Pharma, Orionintie 1</s1>
<s2>02100 Espoo</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Department of Neurology, University of Helsinki</s1>
<s2>Helsinki</s2>
<s3>FIN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA15>
<fA20><s1>401-410</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15741</s2>
<s5>354000118596840410</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>68 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0414553</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Advances in neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tyrosine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Tyrosine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tirosina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dystonie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dystonia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Distonía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Hydroxylase</s0>
<s2>FE</s2>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hydroxylase</s0>
<s2>FE</s2>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hydroxylase</s0>
<s2>FE</s2>
<s5>18</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>19</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>19</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>21</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>21</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>21</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Aminoacide</s0>
<s5>25</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Aminoacid</s0>
<s5>25</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Aminoácido</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Muscle strié pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>286</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0414553 INIST</NO>
<ET>Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss</ET>
<AU>FURUKAWA (Yoshiaki); GORDIN (Ariel); KAAKKOLA (Seppo); TERÄVÄINEN (Heikki)</AU>
<AF>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health-Clarke Division/Toronto, Ontario/Canada (1 aut.); Research Centre, Orion Pharma, Orionintie 1/02100 Espoo/Finlande (1 aut.); Department of Neurology, University of Helsinki/Helsinki/Finlande (2 aut., 3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Advances in neurology; ISSN 0091-3952; Coden ADNRA3; Etats-Unis; Da. 2003; Vol. 91; Pp. 401-410; Bibl. 68 ref.</SO>
<LA>Anglais</LA>
<CC>002B17G</CC>
<FD>Dopa; Tyrosine; Dystonie; Traitement; Hydroxylase; Chimiothérapie; Homme; Aminoacide</FD>
<FG>Oxidoreductases; Enzyme; Extrapyramidal syndrome; Mouvement involontaire; Muscle strié pathologie; Système nerveux pathologie; Trouble neurologique; Encéphale pathologie; Système nerveux central pathologie</FG>
<ED>Dopa; Tyrosine; Dystonia; Treatment; Hydroxylase; Chemotherapy; Human; Aminoacid</ED>
<EG>Oxidoreductases; Enzyme; Extrapyramidal syndrome; Involuntary movement; Striated muscle disease; Nervous system diseases; Neurological disorder; Cerebral disorder; Central nervous system disease</EG>
<SD>Dopa; Tirosina; Distonía; Tratamiento; Hydroxylase; Quimioterapia; Hombre; Aminoácido</SD>
<LO>INIST-15741.354000118596840410</LO>
<ID>03-0414553</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A51 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A51 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0414553
   |texte=   Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss

Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri